A delayed clinical trial actually boosted Bristol Myers Squibb’s stock.
Here’s why.
-
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes
for Cobenfy as an Alzheimer’s treatment, even though the outcome of a
late-stage ...
36 minutes ago







An article in the overseas edition of the People's Daily on Tuesday said the last-minute deal revealed the long-term risks to China's massive holdings of US Treasuries.
ReplyDelete